- Campoccia D et al. Semisynthetic Resorbable Materials from Hyaluronan Esterification. Biomaterials, 1998; 19: 2101-27.
- Caravaggi C. et al. Safety and Efficacy of a Dermal Substitute in the Coverage of Cancellous Bone after Surgical Debridement for Severe Diabetic Foot Ulcerations. EWMA Journal, 2009. Vol.9 No.I 11-14.
- Chen WY and Abatangelo G. Functions of Hyaluronan in Wound Repair. Wound Repair Regen, 1999; 7 (2): 79-89.
- Edmonds M and Foster A. Hyalofill: A New Product for Chronic Wound Management. The Diabetic Foot. Vol. 3 No 1. 2000. 29-30.
- Esposito G et al. Use of Hyaluronan Dressings Following Dermabrasion Avoids Escharatomy and Facilitates Healing in Pediatric Burn Patients. Plast. Reconstr. Surg, 2007; 119(7): 2346-2347.
- Gravante G et al. The Use of Hyalomatrix PA in the Treatment of Deep Partial Thickness Burns. J Burn Care Res, 2007; 28(2): 269-274.
- Longaker MT et al. Fetal Wound Healing: Progress Report and Future Directions. Surgery, 2001; 130: 785-787.
- Merone A et al. The Treatment of Face Burns with Jaloskin. Annals of Burns and Fire Disasters. vol. XIV- n. 4 – December 2001. 178-180.
- Myers SR et al. Hyalomatrix PA: A Temporary Epidermal Barrier, Hyaluronan Delivery, and Neodermis Induction System for Kerotinocyte Stem Cell Therapy. Tissue Engineering, 2007; 13(11): 2733-2741.
- Price D et al. A Comparison of Tissue Engineered Hyaluronic Acid Dermal Matrices in a Human Wound Model. Tissue Engineering, 2006; 12(10):3001-3011
- Tadecucci P et al. An Evaluation f Hyalofill-F plus Compression Bandaging in the Treatment of Chronic Venous Ulcers. Jorunal of Wound Care. Vol. 13 No.5, May 2004. 202-204.
- Toole BP. Hyaluronan in Morphogenesis. J Intern Med, 1997; 242: 35-40.
- West DT et al. Angiogenesis Induced by Degradation Products of Hyaluronic Acid. Science, 1985; 285: 1324-1326.



One of the major components of the extracellular matrix, Hyaluronic Acid (HA) is a naturally occurring, ubiquitous glycosaminoglycan found in many of the organs and tissues of the human body including skin, joints and eyes. It is also referred to as “hyaluronan” or “hyaluronate”.
HA is known to play a key role in all fundamental phases of the highly complicated wound healing process such as inflammation, granulation, angiogenesis and re-epithelialization.
Despite its utmost significance, the application of hyaluronic acid on damaged dermal tissue in a direct, stable and sustained manner was only made possible with the HYAFF® technology. Thus, a new era of fast, reliable and cost-effective dermal repair has begun.
HYAFF® is the patented esterified version of pure hyaluronic acid and it has a bioactive effect on dermal regeneration. All HYAFF® products listed in this brochure utilize the below mentioned clinical benefits of HA.


- Thanks to its direct interaction with other extracellular matrix components as well as cells, hyaluronic acid has the capability to effect the wound environment on a macro and micro level. Therefore, it plays a prominent role in regulating the otherwise chaotic wound environment and the complicated healing processes from inflammation on.
- As it is highly hygroscopic, HA maintains the moisture balance on the wound bed which is vital for all stages of dermal regeneration.
- Enhances cell migration and proliferation.
- Stimulates neo-angiogenesis.
- Scavenges free radicals that are detrimental to healing and promotes a healthy granulation.
- Contributes to the structural integrity of the new tissue by supporting and regulating collagen production. Thus minimizing scar formation, it helps restore functional and esthetic qualities of the skin.
- Abundant also in epidermis, HA promotes a fast and orderly re-epithelialization and thus helps complete the final step of the wound closure process with a high-quality clinical outcome.